Hormonal
Combining naltrexone SR (32 mg/day) and bupropion SR (360 mg/day) with intensive behavior modification produces significantly greater weight loss (9.3%) and cardiometabolic improvements compared to behavior modification alone (5.1%) in obese adults over 56 weeks.
If you have obesity, adding this specific combination of naltrexone and bupropion to a structured diet and exercise program can nearly double your average weight loss compared to diet and exercise alone. The medication is taken twice daily and requires a slow start to minimize nausea. It is most effective for those without diabetes or heart conditions.
At week 56, weight loss was 5.1 ± 0.6% with placebo + BMOD vs. 9.3 ± 0.4% with NB32 + BMOD (P < 0.001).
Why this rating
Large-scale (N=793), randomized, double-blind, placebo-controlled trial (Phase 3).
Source
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial
Thomas A. Wadden et al. · Obesity · 2010
DOI 10.1038/oby.2010.147
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →